Atara Biotherapeutics, Inc. · NASDAQ:ATRA
Atara Biotherapeutics — Q3 2021 Earnings Presentation
68 slides from Atara Biotherapeutics's earnings presentation, Nov 4, 2021
Slide 1: Investor Presentation
Ola EBV+ PTLD Advocate Investor Presentation November 4, 2021 Nasdaq: ATRA 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prese
Slide 3: Pioneering Off-the-Shelf, Allogeneic T-cell Immunotherapies
Pioneering Off-the-Shelf, Allogeneic T-cell Immunotherapies Our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and Allison a commitment to excellence Ola PTLD Advocate PTLD Advocate Ayden PTLD Advocate Dan Swapna PTLD Advocate MS Advocate Mit
Slide 4: Highly Experienced Executive Team Dedicated to Transforming the Lives of Patients
Highly Experienced Executive Team Dedicated to Transforming the Lives of Patients Pascal Touchon Jakob Dupont, M.D. President and Utpal Koppikar Chief Financial Officer Head of Research and Chief Executive Officer Development Joe Newell AJ Joshi, M.D. Kristin Yarema, Ph.D. Chief Operations Officer C
Slide 5: We Are a Leading Allogeneic T-Cell Immunotherapy Company
We Are a Leading Allogeneic T-Cell Immunotherapy Company Differentiated Allogeneic Cell Therapy Platform Scalable EBV T-cell platform and technologies to develop multiple allogeneic cell therapies Tab-cel®: First-In-Kind, Late-Stage, Oncology Program Expect to complete the MAA submission in November
Slide 6: We Are Rapidly Advancing Across Multiple Fronts
We Are Rapidly Advancing Across Multiple Fronts Today 2022 Potential for first allogeneic T-cell Tab-cel® Working toward MAA and immunotherapy on the market in 2022 BLA submissions Growing open label clinical and Disability improvement data from RCT ATA188 translational dataset suggesting has potent
Slide 7: A Differentiated Approach to Allogeneic Cell Therapy, with No Gene Editing of the T-Cell Receptor
Atara: A Differentiated Approach to Allogeneic Cell Therapy, with No Gene Editing of the T-Cell Receptor EBV-Targeting Engineered T-Cell Products: Oncology Products: Tab-cel® and ATA188 Next-gen CAR T or TCR T CAR EBV TCR EBV TCR Next-Gen CAR ATA3219 CD19 1XX CAR HLA Technologies HLA Healthy Donor m
Slide 8: Atara's Next-Generation Solid Tumor CAR T cells
Atara’s Next-Generation Solid Tumor CAR T cells: EBV CAR T Cells Expressing MSLN-1XX CAR and PD1DNR m912 CD28 1XX PD1 5' scFv TM-IC Zeta P2A DNR 3' Non-EBV Targeted TCRs Peripheral Blood T Cells Diversity of TCR Specificities CAR Retroviral Vector EBV Expansion & Targeted Cryo TCR MSLN-1XX CAR Banki
Slide 9: Our Vision is to Transcend the Limitations of Current Cell Therapy by Harnessing EBV T-cells
Our Vision is to Transcend the Limitations of Current Cell Therapy by Harnessing the Power of EBV T-cells Autologous Other Allogeneic Atara Bio Allogeneic Cell Therapy Cell Therapy Cell Therapy Proven only in Limited long-term Durable response in Durable Efficacy some heme clinical data PTLD and PMS
Slide 10: Robust T-Cell Immunotherapy Pipeline
Robust T-Cell Immunotherapy Pipeline Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Registration Next Milestone Nov ’21: MAA RR EBV+ PTLD following ALLELE Study EBV Q2 ’22 : BLA HCT and SOT submissions Tab-cel® Multi-Cohort: EBV+ 2023: Ph2 Study EBV (tabelecleucel) cancers(1) data exp
Slide 11: Our Platform is Nearing Commercial Scale Readiness
Our Platform is Nearing Commercial Scale Readiness Dedicated, expandable manufacturing facility − Flexibility to produce multiple T-cell and CAR T immunotherapies − Designed to meet global regulatory standards − Commercial manufacturing validation activities near completion Robust manufacturing
Slide 12: In Q3 2021, We Opened Our New Atara Research Center (ARC)
In Q3 2021, We Opened Our New Atara Research Center (ARC) Research center in Thousand Oaks (CA) housing the Company’s Translational and Pre-Clinical Sciences, Process Sciences, and Analytical Development teams New capabilities will support our current product pipeline, new proprietary product de
Slide 13: Three Strategic Priorities Driving Long-Term Value
Three Strategic Priorities Driving Long-Term Value Tab-cel® ATA188 Next-Gen CAR T First-in-Kind Allogeneic T-Cell Transformative MS Next-Generation Allogeneic Therapy Preparing for Historic Treatment in Randomized CAR T Programs Regulatory Filing Controlled Trial (RCT) Leveraging EBV T Cells • BTD p
Slide 14: Upcoming Key Catalysts
Upcoming Key Catalysts Complete EU Marketing Authorization Application (MAA) submission for patients with EBV+ PTLD Nov. 2021 Tab-cel® (tabelecleucel) Present Phase 3 ALLELE data at ASH Dec. 2021 Complete FDA Biologics License Application (BLA) rolling submission for patients with EBV+ PTLD Q2 2022
Slide 15: Atara is Well-Capitalized With Planned Cash Runway Into Q2 2023
Atara is Well-Capitalized With Planned Cash Runway Into Q2 2023 Nasdaq: ATRA $357.2 million 88.4 million Cash, cash equivalents, and short-term Shares Outstanding investments as of September 30, 2021 as of September 30, 2021 * Atara Biotherapeutics, Inc. $90.2 million $59.0 million Q3 2021 Q3 2021 O
Slide 16: Atara Strategic Priorities to Create Value: Tab-cel
Atara Strategic Priorities to Create Value: Tab-cel® Tab-cel® (tabelecleucel) Investigational T-cell immunotherapy for EBV-associated ultra-rare diseases FDA breakthrough designation and EMA PRIME for EBV+ PTLD ATA188 CAR T 16
Slide 17: A Common Virus—EBV—Causes Rare and Serious Cancers In Patients With Impaired Immune Function
A Common Virus—EBV—Causes Rare and Serious Cancers In Patients With Impaired Immune Function EBV is a common driver of IA-LPDs EBV is a ubiquitous yet typically dormant virus − Once infected, healthy patients harbor lifelong infection Tab-cel® has the potential to transform that is usually kept in
Slide 18: EBV-Associated Post-Transplant Lymphoproliferative Disease
EBV-Associated Post-Transplant Lymphoproliferative Disease Aggressive, Often Deadly Cancer with No Approved Therapy Rare B-cell lymphoma that occurs in immunosuppressed patients after transplant Average age under 40 years vs. around 65 years for NHL — Bone marrow transplant (HCT) Ayden EBV+ PTLD r
Slide 19: Tab-cel Long-Term Outcomes for Patients with EBV+ PTLD in Phase 2 and EAP Studies
Tab-cel® – Long-Term Outcomes for Patients with EBV+ PTLD in Phase 2 and EAP Studies(1,2) Probability of Survival All, n=35, 1-yr OS=68.3% All, n=14, 1-yr OS=64.3% Probability of Survival Non Response, n=11, 1-yr OS=24.2% Non Response, n=7, 1-yr OS=28.6% 1.0 Response, n=24, (20CRs, 4PRs) 1-yr OS=87.
Slide 20: Interim Analysis of Tab-cel Phase 3 ALLELE Data Presented at ASH 2021
Interim Analysis of Tab-cel® Phase 3 ALLELE Data Presented at ASH 2021 Demonstrate 50% ORR and Impressive Overall Survival at 1 Year IORA: Phase 3 Interim Analysis ORR Interim Analysis by IORA for for EBV+ PTLD patients who failed rituximab Phase 3 Pivotal Study 50% 50% Based on data cut from Q2 2
Slide 21: Recent Positive Regulatory Progress for Tab-cel
Recent Positive Regulatory Progress for Tab-cel® After gaining clarity, alignment on key comparability Completed all necessary regulatory and compliance methodology has been reached with the U.S. Food and steps needed to submit an EU Marketing Authorization Drug Administration (FDA) Application
Slide 22: Tab-cel EBV+ PTLD – Attractive Ultra-Rare Disease Market
Tab-cel® EBV+ PTLD – Attractive Ultra-Rare Disease Market Estimated Incidence in the U.S. in 2019(1) PTLD incidence Low single digits(2) Relapsed/refractory 40%-60% ~48,000 Allogeneic Several hundred transplants EBV+ PTLD patients SOT HCT who have failed ~80% ~20% rituximab ± chemo EBV+ HCT: ~100% P
Slide 23: Market Dynamics in EBV+ PTLD Are Favorable For Rapid Uptake Of A Transformative Targeted Therapy
Market Dynamics in EBV+ PTLD Are Favorable For Rapid Uptake Of A Transformative Targeted Therapy Previously treated EBV+ PTLD is our first planned indication for tab-cel among IA-LPDs Ultra-rare B-cell lymphoma occurring in immunosuppressed post-transplant patients Average age of onset <40 years Sev
Slide 24: Tab-cel – Compelling Value Proposition for EBV+ PTLD Patients and Healthcare System
Tab-cel® – Compelling Value Proposition for EBV+ PTLD Patients and Healthcare System ≥50% ORR in Phase 2, EAP, and Phase 3 IA High and durable No CRS or >80% survival at treatment Excellent safety neurotoxicity observed 2 years in responders in effect(1) profile(1) No treatment- Phase 2 and EAP rela
Slide 25: Targeted, Highly Efficient Commercialization Model for Tab-cel
The Unique Attributes of PTLD and Tab-cel® Allow for a Targeted, Highly Efficient Commercialization Model Proactive HCP engagement PTLD ecosystem early in patient journey Rapid • Finite number of transplant centers and patients monitored routinely Tab-cel’s support in any care setting, • Personalize
Slide 26: Atara Biotherapeutics and Pierre Fabre Launched Strategic Collaboration to Commercialize Tab-cel
Atara Biotherapeutics and Pierre Fabre Launched Strategic Collaboration to Commercialize Tab-cel® Pierre Fabre to Commercialize Tab-cel® for EBV+ Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Pierre Fabre brings significant oncology Atara to receive upfront payment of
Slide 27: Tab-cel – Additional Phase 2 is Underway Which May Support Meaningful Label Expansion
Tab-cel® – Additional Phase 2 is Underway Which May Support Meaningful Label Expansion EBV-205 Phase 2 Study EBV+ AID-LPD and EBV+ PID-LPD Label expansion opportunity for tab-cel Study Populations High unmet need We initiated a tab-cel Phase 2 EBV+ PID-LPD Large potential patient population mu
Slide 28: EBV+ IA-LPDs Present a Meaningful Opportunity to Expand Potential Tab-cel Label
EBV+ IA-LPDs(1) Present a Meaningful Opportunity to Expand Potential Tab-cel® Label U.S. Multi-Cohort Potential Label Expansion Populations – 2019(2) Disease incidence AID-LPD: low single digits IA-LPDs U.S. PID-LPD: high single digits Population at Risk ~205,000 Patients Potentially addressable pop
Slide 29: Atara Strategic Priorities to Create Value: ATA188
Atara Strategic Priorities to Create Value: ATA188 ATA188 CAR T EBV T-cell immunotherapy for progressive multiple sclerosis (MS) 29
Slide 30: Multiple Sclerosis is a Debilitating Disease of the Central Nervous System with Few Treatment Options
Multiple Sclerosis (MS) is a Debilitating Disease of the Central Nervous System with Few Treatment Options High Unmet Need Remains for Patients with Progressive MS Large patient population — ~2.8 million1 patients diagnosed and living with MS worldwide — Up to ~1.2 million MS patients worldwide ha
Slide 31: What Could a Transformative Therapy in Progressive MS Look Like?
What Could a Transformative Therapy in Progressive MS Look Like? ILLUSTRATIVE Time EDSS = 0 (No Disability) Sustained reversal of disability Transformative advance Halted progression Disability Current treatments: ~6 month delay in progression EDSS = 10 (Death) Natural course of progression 31
Slide 32: ATA188 is a Potentially Transformative MS Treatment
ATA188 is a Potentially Transformative MS Treatment Safety Efficacy Activity Targeting Intervention Profile of a Halt or Reverses Targets specific Addresses Safe and Well- Transformative disability Penetrates CNS B cells and underlying tolerated progression plasma cells biology Treatment ✓ ✓ ✓ ✓ ✓ S
Slide 33: ECTRIMS 2021: EDSS and T25FW Results Among Patients in Cohorts 1–4 Who Met SDI Criteria
ECTRIMS 2021: EDSS and T25FW Results Among Patients in Cohorts 1–4 Who Met SDI Criteria Within the First 12 Months and/or During the OLE* Clinically significant improvement Trend for improvement/stable Clinically significant decline Trend for decline Redosed for OLE Year 2 – Cohort 3 dose Redosed fo
Slide 34: ECTRIMS 2021: EDSS and T25FW Results Among Patients Without SDI
ECTRIMS 2021: EDSS and T25FW Results Among Patients in Cohorts 1–4 with OLE Data – Patients Without SDI Clinically significant improvement Trend for improvement/stable Clinically significant decline Trend for decline Redosed for OLE Year 2 – Cohort 3 dose Redosed for OLE Year 3 – Cohort 4 dose 12 15
Slide 35: Increased MTR Suggests Remyelination is Potential Driver for EDSS Improvement
Increased Magnetization Transfer Ratio (MTR) Suggests Remyelination is Potential Driver for EDSS Improvement Observed with ATA188 MTR is an MRI biomarker considered to reflect the density of myelin in the central nervous system − MTR is the most widely used technique in clinical studies to evaluat
Slide 36: Subjects with Sustained EDSS Improvement Have Statistically Significant Increase in MTR
Subjects with Sustained EDSS Improvement Have a Statistically Significant Increase in MTR (Remyelination) at 12 months in Unenhancing T2 Lesions MTR for Unenhancing T2 Lesions MTR for Normal-appearing Brain Tissue Change from Baseline Change from Baseline Change from Baseline Change from Baseline at
Slide 37: MTR Increases in Ph1 ATA188 Study Suggest Remyelination vs MTR Decreases in Siponimod Study
MTR Increases in Ph1 ATA188 Study (SPMS, PPMS) Suggest Remyelination vs MTR Decreases in Ph3 Siponimod Study (SPMS) Siponimod Ph3: Normal Appearing ATA188 Ph1A Normal Appearing White Matter (NAWM) Brain Tissue (NABT) Summary Change from baseline in MTR, adj mean Change from baseline in MTR, adj. mea
Slide 38: ATA188 Shows Statistically Significant Increase in MTR in Unenhancing T2 Lesions
ATA188 Shows, For the First Time in PMS, a Statistically Significant Increase in MTR (Potential Remyelination) in Unenhancing T2 Lesions Normal Appearing Brain Tissue (NABT) Unenhancing T2 Lesions 6 Months 12 Months 6 Months 12 Months Change from baseline in MTR, mean 0.101 0.079 0.076 0.045 0.028 0
Slide 39: Treatment with ATA188 Led to Sustained EDSS Improvement in Some Patients
In the Phase 1 and OLE, Treatment with ATA188 Led to Sustained EDSS Improvement in Some Patients Suggesting a Possible Reversal of Disease Progression 3.0 4.5 ATA188 Pt A* (at 12 mo.) (Baseline) 3.0 5.5 ATA188 Pt E (at 30 mo.) (Baseline) 3.5 5.5 (at 33 mo.) (Baseline) ATA188 Pt H 2.0 4.5 5.5 (at 15
Slide 40: ECTRIMS 2021: Summary of Data and Findings
ECTRIMS 2021: Summary of Data and Findings Updated results from the ongoing OLE demonstrate A total of 24 patients* enrolled in the Ph 1a study continued safety and tolerability of ATA188 with the longest (initial 12 mo), 18 of whom continued into the OLE observed patients receiving up to 3 annual
Slide 41: Positive Commentary on ECTRIMS Data Reinforces Transformative Potential of ATA188
Positive Commentary on ECTRIMS Data Reinforces Excitement for and Transformative Potential of ATA188 Although larger randomized controlled trials are needed to The important point for me is the MTR is an objective measure done confirm these results, this is potentially the first treatment to using s
Slide 42: Significant Progress with FDA and Advancing Phase 2 RCT (EMBOLD) for ATA188
We Have Made Significant Progress with FDA and are Advancing our Phase 2 RCT (EMBOLD) for ATA188, with an Interim Analysis Planned in H1 2022 FDA Registrational Feedback Received for Current RCT Primary endpoint: measuring disability improvement is acceptable; FDA preference for EDSS ‒ Study durat
Slide 43: Multi-Billion Dollar Potential for a Transformative Therapy in Progressive MS
Multi-Billion Dollar Potential for a Transformative Therapy in Progressive MS Estimated US Market Forecast for Progressive MS (2025) 5 YR CAGR: 57% Other therapies up to ~9% 43% Anti-CD20s ’20 ’25 Transformative ~$5B - $7B Therapy: ~45%+ Share for Best- PMS Overall ~25% - 50% Higher in-Class Treatme
Slide 44: Atara Strategic Priorities to Create Value: CAR T
Atara Strategic Priorities to Create Value: CAR T CAR T ATA2271/ATA3271 (Solid Tumors) ATA3219 (B-cell malignancies) Other CAR T 44
Slide 45: Leveraging Our EBV Platform to Optimize CAR and TCR Therapies
Leveraging Our EBV Platform to Optimize CAR and TCR Therapies Off-the-shelf, allogeneic Off-the-shelf CAR T 1 EBV T-cell platform 3 with broad applications Next-Generation Technologies Next-generation Multi-targeted CARs 2 CAR technologies − Dual targeting with gating (“AND”/“OR”) to avoid EBV EBV o
Slide 46: Atara and Bayer Strategic Collaboration for Mesothelin-Targeted CAR T Cell Therapies
Atara Biotherapeutics and Bayer Launched Strategic Collaboration for Mesothelin-Targeted CAR T Cell Therapies For Solid Tumors Worldwide license agreement and research, development and manufacturing collaboration to develop Atara’s allogeneic off-the-shelf mesothelin CAR T program (ATA3271) and auto
Slide 47: Global Strategic Collaboration With Bayer Continues to Progress Well
Global Strategic Collaboration for ATA2271 and ATA3271 With Bayer Continues to Progress Well with Advancement of the Mesothelin-partnered CAR T Immunotherapy Programs Mesothelin is a well-established target associated with aggressive solid tumors Unique ScFv that binds to mesothelin above cancer
Slide 48: ATA3219: Developing Potential Best in Class Off-the-Shelf Allogeneic CD19 Program
ATA3219: Developing Potential Best in Class Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies, With IND Expected in Q1 2022 Academic program generated proof of principle for EBV T-cell platform potential to generate off-the-shelf, allogeneic CAR T therapies with high EBV and durable re
Slide 49: Thank You
ATARA BIO Thank You Nasdaq: ATRA
Slide 50: Appendix
Appendix NAV, XX a ATARA BIO 50
Slide 51: Tab-cel
Tab-cel® ATARA BIO’ 51
Slide 52: Tab-cel – Off-the-Shelf, Allogeneic T-Cell Immunotherapy with Potential to Transform Treatment of EBV+ PTLD
Tab-cel® – Off-the-Shelf, Allogeneic T-Cell Immunotherapy with Potential to Transform Treatment of EBV+ PTLD NEW Week -10 Week -4 Week 0 Week 10 Week 15 Week 29 36-year-old with Increase in Disease Tab-cel® response: Continued Complete Fanconia anemia tumor burden progression after 3 rapid decrease
Slide 53: Tab-cel Has the Potential to Benefit Other Patients with EBV-Driven Cancers
Tab-cel® Has the Potential to Benefit Other Patients with EBV-Driven Cancers Beyond Previously Treated EBV+ PTLD EBV-205 Phase 2 Study Design All Cohorts Include 1L Patients ENDPOINTS EBV+ PID LPD Additional Treatment Primary: Overall EBV+ AID LPD Response Rate (ORR) Quarterly EBV+ PTLD CNS End-of
Slide 54: ATA188
ATA188 NAV, XX a ATARA BIO 5a
Slide 55: ATA188: A bold vision to transform MS therapy
ATA188 Precision targeting to select EBV antigens limits off-target A bold vision to activity transform MS therapy Off-the-shelf T-cells delivered from inventory Phase 1 trial successfully demonstrated safety and No pretreatment required in the clinical trial protocol Two-hour monitoring following 5
Slide 56: The Role of EBV in Multiple Sclerosis
The Role of EBV in Multiple Sclerosis CONFIDENTIAL 56
Slide 57: Growing Evidence that EBV Has a Major Role in the Pathogenesis of Multiple Sclerosis
Growing Evidence that EBV Has a Major Role in the Pathogenesis of Multiple Sclerosis • Prior EBV infection is necessary for a patient to develop MS 1,4 • MS may be mediated by B cells that are infected with EBV 2 • Defective elimination of EBV-infected autoreactive B cells by CD8+ T-cells results in
Slide 58: Auto-reactive EBV-Infected B cells and Plasma Cells Normally Controlled by EBV T-cells
Auto-reactive EBV-Infected B cells and Plasma Cells Normally Controlled by EBV T-cells Adapted from Pender MP. Neuroscientist 2011; 17:351-367. 58
Slide 59: MS Treatment: Modest Efficacy Benefit from Current Options
MS Treatment: Modest Efficacy Benefit from Current Options Active Secondary Progressive MS Primary Progressive MS 6-mth CDP Siponimod vs. Placebo in SPMS (EXPAND) 24-Wk CDP Ocrelizumab vs. Placebo in PPMS (ORATORIO) 26% 36% 20% 30% • Current therapies delay progression but do not fundamentally alter
Slide 60: Ongoing Open-Label Extension Period will Allow Patients to be Retreated Annually
Ongoing Open-Label Extension Period will Allow Patients in Phase 1 Study to be Retreated Annually with ATA188 Phase 1 Study Schema DOSE-ESCALATION (Year 1) OPEN-LABEL EXTENSION Cohorts 1–4, N = 6 per cohort (Years 2‒5) DLT Assessment DLT (35 Days) Patients Who Assessment Complete Year Single cycle o
Slide 61: We Have Increased our Investment in the ATA188 Program
Based on Encouraging Clinical Data, We Have Increased our Investment in the ATA188 Program ATA188 Investment Summary Expanded to at least 80 patients in Phase 2 double-blind placebo-controlled study Changed primary endpoint to EDSS improvement endpoint while maintaining other disability improvement
Slide 62: Updated Endpoints in the ATA188 Phase 2 Randomized, Placebo-Controlled Study
We Have Increased Investment and Updated Endpoints in the ATA188 Phase 2 Randomized, Placebo-Controlled Study in at Least 80 Progressive MS Patients Phase 2 Randomized Placebo-Controlled Study Schema (EMBOLD) KEY ENDPOINTS DOUBLE-BLIND PERIOD OPEN-LABEL EXTENSION Primary (clinical): EDSS at 12m R
Slide 63: Biologics-Like Supply Chain for ATA188 at Commercial Scale
We Have Demonstrated Each Element of Our Platform to Support a Biologics-Like Supply Chain for ATA188 at Commercial Scale Data confirms we can scale up Current inventory model projects coverage manufacturing process into bioreactors of ~95% of MS patients with ~10 cell lines PRODUCTIVITY OF ONE LEUK
Slide 64: Change in MTR is Associated with Change in EDSS Score in Unenhancing T2 Lesions
Change in MTR is Associated with Change in EDSS Score in Unenhancing T2 Lesions at Six and 12 Months MTR for Unenhancing T2 Lesions MTR for Normal-appearing Brain Tissue Change from Baseline Change from Baseline Change from Baseline Change from Baseline at 6 Months at 12 Months at 6 Months at 12 Mon
Slide 65: CAR T Portfolio
CAR T Portfolio NAV, XX a ATARA BIO 65
Slide 66: Atara Off-the-Shelf, Allogeneic CAR T Immunotherapy Strategy
Atara Off-the-Shelf, Allogeneic CAR T Immunotherapy Strategy Rapidly advance Invest autologous CAR T for in world-class T-cell proof-of-concept manufacturing Collaborate followed by off-the-shelf, with academic allogeneic EBV CAR Ts Leverage leaders applying T-cell research, development next-gen and
Slide 67: Exclusive License to Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors from MSK
Exclusive License to Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors from MSK Mesothelin is an attractive target associated with aggressive solid tumors (1,2) Aberrant mesothelin expression promotes cancer cell proliferation and confers resistance to apoptosis — Associated with mesothelio
Slide 68: Atara CAR / TCR Pipeline – Applying Next-Generation Technologies
Atara CAR / TCR Pipeline – Applying Next-Generation Technologies in Collaboration with Academic & Industry Leaders Indication Target Technologies (1) Autologous PD-1 DNR ATA2271 Solid tumors(2) Mesothelin 1XX co-stimulation (1) Off-the-shelf, allogeneic PD-1 DNR ATA3271 Solid tumors(2) Mesothelin 1X
Atara Biotherapeutics — Q3 2021 Earnings Presentation on 6ix